Serine/Threonine Protein Kinase Pim 2 Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1 Pipeline Review, H1 2018
Summary
Serine/Threonine Protein Kinase Pim 2 Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1 Serine/threonineprotein kinase Pim2 is an enzyme encoded by the PIM2. It is involved in cell survival and cell proliferation. It regulates capdependent protein translation in a mammalian target of rapamycin complex 1 mTORC1independent manner and in parallel to the PI3KAkt pathway. It mediates survival signaling through phosphorylation of BAD, which induces release of the antiapoptotic protein BclX L/BCL2L1. It promotes cell survival in response to a variety of proliferative signals via positive regulation of the IkappaB kinase/NFkappaB cascade.
Serine/Threonine Protein Kinase Pim 2 Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1 pipeline Target constitutes close to 8 molecules. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 6 and 1 respectively. Report covers products from therapy areas Oncology and Immunology which include indications Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Chronic Lymphocytic Leukemia CLL, Pancreatic Cancer, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Bladder Cancer, Breast Cancer, Colon Cancer, Hematological Tumor, Liver Cancer, Lung Cancer, Lymphoma, NonSmall Cell Lung Carcinoma, Prostate Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Solid Tumor and Transitional Cell Carcinoma Urothelial Cell Carcinoma.
The latest report SerineThreonine Protein Kinase Pim 2 Pipeline Review, H1 2018, outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 2 Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Serine/Threonine Protein Kinase Pim 2 Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1 targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 2 Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1
The report reviews Serine/Threonine Protein Kinase Pim 2 Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Serine/Threonine Protein Kinase Pim 2 Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1 targeted therapeutics and enlists all their major and minor projects
The report assesses Serine/Threonine Protein Kinase Pim 2 Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 2 Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 2 Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 2 Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope